Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
STOK - Stoke Therapeutics, Inc.
Market Cap 276.62M P/E - EPS this Y 2.90% Ern Qtrly Grth -
Income -104.7M Forward P/E -2.29 EPS next Y -9.10% 50D Avg Chg -41.00%
Sales 8.78M PEG 0.24 EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book 1.29 EPS next 5Y -21.40% 52W High Chg -73.00%
Recommedations 1.80 Quick Ratio 6.54 Shares Outstanding 52.12M 52W Low Chg 6.00%
Insider Own 4.59% ROA -29.62% Shares Float 35.46M Beta 0.76
Inst Own 80.13% ROE -60.80% Shares Shorted/Prior 5.53M/3.55M Price 6.26
Gross Margin 100.00% Profit Margin - Avg. Volume 398,641 Target Price 23.67
Oper. Margin -1,055.89% Earnings Date May 2 Volume 446,530 Change -1.88%
Healthcare | Biotechnology | United States
About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics, Inc. News
04/25/24 Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
04/17/24 Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
04/04/24 Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
10:40 PM Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
07:50 AM Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
03/26/24 Stoke Therapeutics Announces Proposed Public Offering
03/26/24 Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
03/26/24 Stoke shares surge on updated results for Dravet drug
03/25/24 Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
03/25/24 Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
03/25/24 Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
02/29/24 Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
02/28/24 Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
02/26/24 Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
02/25/24 7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/19/24 Triple Threat: 3 Stocks to Buy for 3X Upside Potential
02/15/24 Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
02/15/24 Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?
01/17/24 Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
01/11/24 Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
STOK Chatroom

User Image intratio Posted - 9 hours ago

$STOK https://www.intratio.com/stock-forecast/STOK Our trained A.I. foresees that the value of this company will shortly go down and its stock price is in line with its long-term fundamentals

User Image StockConsultant Posted - 20 hours ago

$STOK Stoke Therapeutics stock back to 11.39 gap support with high trade quality, https://stockconsultant.com/?STOK

User Image Stocks4thought Posted - 1 day ago

$STOK Great recovery.

User Image V792 Posted - 1 day ago

$STOK is there anyone read the latest news?

User Image QKerno Posted - 1 day ago

$STOK

User Image Stocks4thought Posted - 2 days ago

$STOK Stoked

User Image intratio Posted - 4 days ago

$STOK https://www.intratio.com/stock-forecast/STOK The predictive model foresees that this stock s price action is not set up well for the near-term and has no ground to be a long-term opportunity

User Image piku99 Posted - 4 days ago

$STOK see the opportunity

User Image insiderbuyingselling Posted - 1 week ago

$STOK new insider selling: 3600000 shares. http://insiderbuyingselling.com/?t=STOK

User Image Randomize Posted - 1 week ago

$STOK piece of shit go past 13.50

User Image CheckingMorons Posted - 2 weeks ago

$STOK what takes so long hit my limit order 13.20 🥱🥱

User Image CheckingMorons Posted - 2 weeks ago

$STOK 13.20 before close hope so

User Image CheckingMorons Posted - 2 weeks ago

$STOK lol weird price dropped to 12.50 for no reason back to over 13 before close lol easy buy now

User Image piku99 Posted - 2 weeks ago

$STOK intraday into Tuesday.

User Image piku99 Posted - 2 weeks ago

$STOK almost there.. when we fly I prefer suspense tomorrow and we fly Tuesday and multi day runner .. show me 20-24

User Image Randomize Posted - 2 weeks ago

$STOK this bs need to go back to $15

User Image erevnon Posted - 2 weeks ago

Needham reiterates Stoke Therapeutics $STOK at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image piku99 Posted - 2 weeks ago

$STOK not quite yet. Glory soon .. 13.4 close any day could mean 10*2

User Image Randomize Posted - 2 weeks ago

$STOK if stays green this week I'm assuming offering has closed. We'll see if PR soon

User Image matmasr Posted - 2 weeks ago

Latest Moon Shot Alerts of Q1 2024 $STOK $SIDU $NNOX $NKTX

User Image scalp_scalpnyc Posted - 3 weeks ago

$STOK 20++++

User Image Stock_Titan Posted - 3 weeks ago

$STOK Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/STOK/stoke-therapeutics-to-present-at-the-23rd-annual-needham-virtual-utxvvo1eyomp.html

User Image Thinkfastactfast Posted - 3 weeks ago

$STOK I'm new, but I'm stoked!

User Image BioRich Posted - 3 weeks ago

$EIGRQ great recovery. I love seeing this after the bloodbath yesterday. I did this with $SAGE and $STOK a few years ago and did well

User Image Zinvest Posted - 3 weeks ago

$STOK I’m in!

User Image piku99 Posted - 3 weeks ago

$STOK imho, getting ready for the 100% day, Tuesday likely will see the surge

User Image Randomize Posted - 3 weeks ago

$STOK shorts doing this dirty

User Image spliffmeister Posted - 3 weeks ago

$STOK pumppp

User Image spliffmeister Posted - 3 weeks ago

$STOK

User Image HUSA_TO_100 Posted - 3 weeks ago

$ATOS Last week $AVTX went from around $4 to as high as $30 on some good News and $STOK went from $6 to $16 on a positive Phase 1 data. With how Bios are flying left and right this year, any positive data and this will Fly to Double Digits 🤑

Analyst Ratings
Needham Buy Apr 11, 24
Cantor Fitzgerald Overweight Apr 4, 24
Wedbush Outperform Mar 26, 24
Canaccord Genuity Buy Mar 26, 24
JP Morgan Neutral Mar 26, 24
TD Cowen Buy Mar 26, 24
HC Wainwright & Co. Buy Mar 26, 24
Needham Buy Mar 26, 24
Needham Buy Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ticho Barry Chief Medical Office.. Chief Medical Officer Jan 02 Sell 5.7352 10,000 57,352 16,981 01/04/24
Ticho Barry Chief Medical Office.. Chief Medical Officer Jul 03 Sell 10.5982 15,000 158,973 25,895 07/06/23
Ticho Barry Chief Medical Office.. Chief Medical Officer Jun 01 Sell 11.1309 15,000 166,964 40,895 06/05/23
Ticho Barry Chief Medical Office.. Chief Medical Officer May 04 Sell 10.00 653 6,530 55,895 05/08/23
Ticho Barry Chief Medical Office.. Chief Medical Officer May 01 Sell 10.05 55,177 554,529 56,548 05/03/23
Ticho Barry Chief Medical Office.. Chief Medical Officer Jan 31 Sell 10.01 6,172 61,782 124,723 02/02/23
Kaye Edward M. MD CEO CEO May 25 Option 0.60 15,000 9,000 25,000 05/26/22
Tulipano Stephen J CFO CFO Feb 24 Option 4.48 30,000 134,400 5,602 02/24/21
Tulipano Stephen J CFO CFO Feb 24 Sell 59.14 30,000 1,774,200 602 02/24/21
TZIANABOS ARTHUR Director Director Feb 23 Option 2.19 10,000 21,900 10,000 02/23/21
TZIANABOS ARTHUR Director Director Feb 23 Sell 60.67 10,000 606,700 02/23/21
Ticho Barry Chief Medical Office.. Chief Medical Officer Dec 21 Option 2.19 1,365 2,989 174,767 12/21/20
Ticho Barry Chief Medical Office.. Chief Medical Officer Dec 21 Sell 57.93 1,365 79,074 173,402 12/21/20
Nash Huw M. COO & CBO COO & CBO Dec 18 Option 0.6 50,000 30,000 8,015 12/18/20
Nash Huw M. COO & CBO COO & CBO Dec 18 Sell 60 50,000 3,000,000 12/18/20
Kaye Edward M. MD CEO CEO Dec 18 Sell 60 25,000 1,500,000 12/18/20
Nash Huw M. COO & CBO COO & CBO Nov 10 Option 1.4 50,000 70,000 50,000 11/10/20
Nash Huw M. COO & CBO COO & CBO Nov 10 Sell 45 50,000 2,250,000 11/10/20
Tulipano Stephen J CFO CFO Nov 04 Option 4.48 70,000 313,600 33,870 11/04/20
Tulipano Stephen J CFO CFO Nov 04 Sell 39.48 70,000 2,763,600 602 11/04/20
Liau Gene EVP Research & Precl.. EVP Research & Preclinical Dev Oct 13 Option 0.6 1,649 989 15,149 10/13/20
Liau Gene EVP Research & Precl.. EVP Research & Preclinical Dev Oct 13 Sell 40 1,649 65,960 13,500 10/13/20
Nash Huw M. COO & CBO COO & CBO Oct 05 Option 2.19 5,700 12,483 5,700 10/05/20
Nash Huw M. COO & CBO COO & CBO Oct 05 Sell 34.6 5,700 197,220 10/05/20
Nash Huw M. COO & CBO COO & CBO Sep 10 Sell 30 47,919 1,437,570 09/10/20
Nash Huw M. COO & CBO COO & CBO Sep 10 Option 2.19 47,919 104,943 17,201 09/10/20